The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.
News & Analysis: Portola Pharmaceuticals
PTLA earnings call for the period ending March 31, 2019.
First-quarter financial results are failing to spark investor optimism on concerns over cash burn.
This commercial-stage company's success depends heavily on the demand for one drug.
PTLA earnings call for the period ending December 31, 2018.
The company's latest quarterly update is sparking optimism that sales might accelerate.
The company's struggling to make the shift to commercial-stage biotech, and recent news raises questions on when this will change.
This biotech is rethinking its priorities as it tries to successfully make the leap to a commercial-stage company.
The biotech specialist is transitioning to a new management team under difficult operating conditions.
Unimpressive launches of two drugs have investors wondering if the biotech can turn things around.